Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Advances in mitotic inhibitors for cancer treatment.

Jiang N, Wang X, Yang Y, Dai W.

Mini Rev Med Chem. 2006 Aug;6(8):885-95. Review.

PMID:
16918495
2.

Mitotic drug targets and the development of novel anti-mitotic anticancer drugs.

Schmidt M, Bastians H.

Drug Resist Updat. 2007 Aug-Oct;10(4-5):162-81. Epub 2007 Jul 31. Review.

PMID:
17669681
3.

Mitotic drug targets.

Kaestner P, Bastians H.

J Cell Biochem. 2010 Oct 1;111(2):258-65. doi: 10.1002/jcb.22721.

PMID:
20518069
4.

Targeting mitosis for anti-cancer therapy.

Sudakin V, Yen TJ.

BioDrugs. 2007;21(4):225-33. Review.

PMID:
17628120
5.

Mitotic spindle checkpoint inactivation by trichostatin a defines a mechanism for increasing cancer cell killing by microtubule-disrupting agents.

Dowling M, Voong KR, Kim M, Keutmann MK, Harris E, Kao GD.

Cancer Biol Ther. 2005 Feb;4(2):197-206. Epub 2005 Feb 8.

PMID:
15753652
6.

Tubulin-associated drug targets: Aurora kinases, Polo-like kinases, and others.

Warner SL, Gray PJ, Von Hoff DD.

Semin Oncol. 2006 Aug;33(4):436-48. Review.

PMID:
16890798
7.

Centmitor-1, a novel acridinyl-acetohydrazide, possesses similar molecular interaction field and antimitotic cellular phenotype as rigosertib, on 01910.Na.

Mäki-Jouppila JH, Laine LJ, Rehnberg J, Narvi E, Tiikkainen P, Hukasova E, Halonen P, Lindqvist A, Kallio L, Poso A, Kallio MJ.

Mol Cancer Ther. 2014 May;13(5):1054-66. doi: 10.1158/1535-7163.MCT-13-0685. Epub 2014 Apr 18.

8.

Mitotic catastrophe as a consequence of chemotherapy.

Mansilla S, Bataller M, Portugal J.

Anticancer Agents Med Chem. 2006 Nov;6(6):589-602. Review.

PMID:
17100562
9.

Kinesin motor proteins as targets for cancer therapy.

Huszar D, Theoclitou ME, Skolnik J, Herbst R.

Cancer Metastasis Rev. 2009 Jun;28(1-2):197-208. doi: 10.1007/s10555-009-9185-8. Review.

PMID:
19156502
10.

If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells.

Roninson IB, Broude EV, Chang BD.

Drug Resist Updat. 2001 Oct;4(5):303-13. Review.

PMID:
11991684
11.

Mitosis and apoptosis: how is the balance set?

Topham CH, Taylor SS.

Curr Opin Cell Biol. 2013 Dec;25(6):780-5. doi: 10.1016/j.ceb.2013.07.003. Epub 2013 Jul 23. Review.

PMID:
23890995
12.

Mitosis-targeting therapies: a troubleshooting guide.

Doménech E, Malumbres M.

Curr Opin Pharmacol. 2013 Aug;13(4):519-28. doi: 10.1016/j.coph.2013.03.011. Epub 2013 Apr 12. Review.

PMID:
23583638
13.

Antimitotic inhibitors.

Campos SM, Dizon DS.

Hematol Oncol Clin North Am. 2012 Jun;26(3):607-28, viii-ix. doi: 10.1016/j.hoc.2012.01.007. Epub 2012 Mar 23. Review.

PMID:
22520982
14.

Vanadocenes as potent anti-proliferative agents disrupting mitotic spindle formation in cancer cells.

Navara CS, Benyumov A, Vassilev A, Narla RK, Ghosh P, Uckun FM.

Anticancer Drugs. 2001 Apr;12(4):369-76.

PMID:
11335794
15.

Aurora kinase inhibitors: a new class of drugs targeting the regulatory mitotic system.

Pérez Fidalgo JA, Roda D, Roselló S, Rodríguez-Braun E, Cervantes A.

Clin Transl Oncol. 2009 Dec;11(12):787-98. Review.

PMID:
20045785
16.

Novel mitotic targets and their small-molecule inhibitors.

Ivachtchenko AV, Kiselyov AS, Tkachenko SE, Ivanenkov YA, Balakin KV.

Curr Cancer Drug Targets. 2007 Dec;7(8):766-84. Review.

PMID:
18220536
17.

Antimitotic drugs in cancer chemotherapy: promises and pitfalls.

Marzo I, Naval J.

Biochem Pharmacol. 2013 Sep 15;86(6):703-10. doi: 10.1016/j.bcp.2013.07.010. Epub 2013 Jul 22. Review.

PMID:
23886991
18.

Cell type variation in responses to antimitotic drugs that target microtubules and kinesin-5.

Shi J, Orth JD, Mitchison T.

Cancer Res. 2008 May 1;68(9):3269-76. doi: 10.1158/0008-5472.CAN-07-6699.

19.

Inactivation of the mitotic checkpoint as a determinant of the efficacy of microtubule-targeted drugs in killing human cancer cells.

Lee EA, Keutmann MK, Dowling ML, Harris E, Chan G, Kao GD.

Mol Cancer Ther. 2004 Jun;3(6):661-9.

20.

Inhibitors targeting mitosis: tales of how great drugs against a promising target were brought down by a flawed rationale.

Komlodi-Pasztor E, Sackett DL, Fojo AT.

Clin Cancer Res. 2012 Jan 1;18(1):51-63. doi: 10.1158/1078-0432.CCR-11-0999. Review.

Items per page

Supplemental Content

Write to the Help Desk